The Role of Recombinant Protein Technology in the Development and Global Impact of Gardasil: Addressing HPV-Induced Cancers and Advancing Vaccine Strategies
HPV (Human Papilloma Virus) is classified into low or high-risk genotype. It is responsible for nearly 5% of all human cancers in both sexes worldwide; certain high-risk genotypes can cause cervical cancer in women. Gardasil vaccine is designed to prevent HPV infections in people aged 9 to 45. By utilizing virus-like particles (VLPs), which are non-infectious mimics of the virus, the vaccine triggers a robust immune response without the risk of causing the disease. One of the major advantages of using recombinant proteins in vaccines like Gardasil is that they are highly immunogenic and allow for precise targeting of specific viral strains. Researchers have proven that Gardasil is safe and effective in clinical trials, although such data is limited for pregnant women. Promoting Gardasil globally will require continued efforts to raise awareness about the vaccine’s benefits, address vaccine hesitancy, and ensure equitable access, particularly in regions where HPV-related cancers are most prevalent.
